肺癌双能量成像、微血管密度和血管内皮生长因子与淋巴结转移的关系  

Correlation between dual source CT dual energy imaging indices,microvessel density,vascular endothelial growth factor and lymphatic involvement in lung cancer

作　　者：顾艳[1] 苗重昌[1] 袁刚[1] 王宗盛[1] 周莹[1] GU Yah;MIAO Chongchang;YUAN Gang;WANG Zongsheng;ZHOU Ying.(Department of Radiology, First People＇s Hospital of Lianyungang , Affiliated Hospital of Xuzhou Medical College, Jiangsu 222002, Chin)

机构地区：[1]徐州医学院附属连云港市第一人民医院放射科,江苏连云港222002

出　　处：《实用医学杂志》2018年第6期1019-1022,共4页The Journal of Practical Medicine

基　　金：江苏省连云港市卫生科技资助项目(编号:ZD201501)

摘　　要：目的探讨双能量成指标和肿瘤微血管密度(MVD)、血管内皮生长因子(VEGF)与非小细胞肺癌淋巴结转移的关系及其价值。方法对62例非小细胞肺癌行双源CT双能量扫描,根据病理结果分为有淋巴结转移组和无淋巴结转移组,并对肿瘤标本行MVD计数和VEGF分析,分析NSCLC两组指标间差异以及与MVD及VEGF的关系。结果 (1)有淋巴结转移组中,NSCLC碘浓度、NIC、动脉期斜率、MVD和VEGF参数值均大于无淋巴结转移组,组间差异均有统计学意义(P<0.05)。(2)碘浓度、NIC、动脉期斜率与MVD、VEGF均成正相关。结论双源CT双能量成像中的碘浓度、NIC、动脉期斜率可作为术前判断肺小细胞肺癌淋巴结转移的重要预测指标之一。Objective To explore the correlation between dual energy imaging indices,microvessel densi-ty（MVD）,vascular endothelial growth factor（VEGF）and lung cancer lymph nodes metastasis and its practical sig-nificance by applying dual source CT（DSCT）dual energy imaging. Methods 62 cases of non-small cell lung can-cer（NSCLC）were underwent DSCT dual energy imaging and divided into groups with and without lymph node me-tastasis according to the results of pathology. The expressions of MVD and VEGF were detected as well. All the indi-ces were compared between the two groups. Results（1）The differences between the lung cancer lymph nodegroups in the iodine concentration,normalized iodine concentration（NIC）,spectrum curve of arterial phase,MVDand VEGF were statistically significant（P〈0.05）.（2）The iodine concentration,NIC and spectrum curve of arte-rial phase were positively correlated with MVD and VEGF. Conclusion Iodine concentration,NIC,and spectrumcurve of arterial phase of DSCT dual energy imaging can be regarded as part of the important indices for preopera-tive diagnosis of lymph node metastasis of NSCLC.

关 键 词：肺癌 病理学 淋巴转移 体层摄影术 X线计算机 

分 类 号：R730.44[医药卫生—肿瘤] R734.2[医药卫生—临床医学]